PMID- 24484319
OWN - NLM
STAT- MEDLINE
DCOM- 20141203
LR  - 20140408
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 43
IP  - 4
DP  - 2014
TI  - TGF-beta favors bone marrow-derived dendritic cells to acquire tolerogenic 
      properties.
PG  - 360-9
LID - 10.3109/08820139.2013.879172 [doi]
AB  - Dendritic cells (DCs) are the most powerful antigen-presenting cells that have an 
      important role in the immunity and immune tolerance. Transforming growth factor beta 
      (TGF-beta) is a pleiotropic cytokine widely expressing in various tissues and cells, 
      which regulates cellular proliferation, differentiation and apoptosis of several 
      immune cells and is considered to be a key factor in inducing immune tolerance. 
      The effect of TGF-beta on DCs is very complex. In this study, we further 
      investigated the effect of TGF-beta on inducing immune tolerance of DCs. DCs were 
      differentiated from mice bone marrow cells in the absence or presence of TGF-beta. 
      The phenotype as well as function was studied in detail. We found that TGF-beta 
      limited the expression of CD40, CD83, CD86 and MHCII in DCs, increased CD45RB and 
      indoleamine 2, 3-dioxygenase (IDO) expression in DCs, promoted IL-10 and limited 
      IL-12 secretion by DCs. Moreover, TGF-beta increased the endocytosis ability of DCs 
      and limited the ability of DCs in activating T cells. These results suggest that 
      TGF-beta affects the immunity of DCs and enhances their tolerogenicity.
FAU - Song, Sha-Sha
AU  - Song SS
AD  - Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of 
      Antiinflammatory and Immune Medicine, Anhui Medical University, Ministry of 
      Education , Hefei 230032 , China.
FAU - Yuan, Ping-Fan
AU  - Yuan PF
FAU - Chen, Jing-Yu
AU  - Chen JY
FAU - Fu, Jing-Jing
AU  - Fu JJ
FAU - Wu, Hua-Xun
AU  - Wu HX
FAU - Lu, J T
AU  - Lu JT
FAU - Wei, W
AU  - Wei W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140131
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Antigens, Surface)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Animals
MH  - Antigens, Surface/genetics/metabolism
MH  - Dendritic Cells/drug effects/*immunology/*metabolism
MH  - Endocytosis/drug effects
MH  - Gene Expression Regulation/drug effects
MH  - Immune Tolerance/*genetics
MH  - Immunophenotyping
MH  - Interleukin-10/biosynthesis
MH  - Interleukin-12/biosynthesis
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Mice
MH  - T-Lymphocytes/drug effects/immunology
MH  - Transforming Growth Factor beta/*metabolism/pharmacology
EDAT- 2014/02/04 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/02/04 06:00
PHST- 2014/02/04 06:00 [entrez]
PHST- 2014/02/04 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.3109/08820139.2013.879172 [doi]
PST - ppublish
SO  - Immunol Invest. 2014;43(4):360-9. doi: 10.3109/08820139.2013.879172. Epub 2014 
      Jan 31.